Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kai-Xin-San (KXS) is a classical traditional Chinese medicine (TCM) prescription first recorded in the 7th century in the ancient text *Beiji Qianjin Yaofang* by Sun Simiao. It is composed of four herbal ingredients: Polygalae Radix (root of Polygala tenuifolia), Ginseng Radix et Rhizoma (root and rhizome of Panax ginseng), Poria (sclerotium of Poria cocos), and Acori Tatarinowii Rhizoma (rhizome of Acorus tatarinowii). The typical ratio is 3:3:2:2. Originally used for amnesia, it has been widely applied to treat depression, cognitive decline, and emotional disorders[1][4][6]. Its pharmacological activities include antidepressant effects—demonstrated in animal models resistant to fluoxetine—and neuroprotective actions through modulation of inflammatory cytokines and upregulation of neurotrophic factors such as BDNF via pCREB signaling pathways[3][4]. The main active constituents are saponins, xanthones, oligosaccharide esters, triterpenoids, volatile oils, and flavonoids; saponins are considered predominant for mental health benefits[1][2]. Mechanistically, KXS appears to regulate neurotransmitter levels and neurotrophic factors in the brain as well as modulate gut microbiota composition[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kai-Xin-San.